Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX)

Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX) Unveils Cannabis-Cancer Genetics Lab

Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX)

Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX) jumped 8.76% in Monday’s trading session after announcing the establishment of a human cannabis-cancer genetics lab that will offer personalized cancer diagnostics. The lab will develop diagnostic tools based on one’s human genome as well as tumor genetics and cannabinoids.

Daily Candle Bar Graph $CNBX

The company has appointed Dr. Moran Grinberg to lead the genetic research team in the wake of the establishment of the cannabis-cancer genetics lab. Moran joins the company with vast experience in clinical pharmacology.

“Our mission is to commercialize a wide range of diagnostic tools that incorporate novel technologies to retrieve better outcomes of cannabinoid treatments. Understanding the genetics of cancer-cannabinoids relations complements our CTC cell count and drug sensitivity capabilities,” said Eyal Ballan, Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX) CTO.

Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX) is a biotechnology company focused on the development and licensing of cannabinoid-based treatments and therapies. The company’s research and development operations are based in Israel and are dedicated to the development of Personalized Anti-Cancer and Palliative treatments. Cannabics utilizes advanced screening systems and personalized bioinformatics tools to come up with personalized natural therapies for cancer.

SIMFO GmbH Collaboration

The company is fresh from signing a collaboration agreement with SIMFO GmbH – a world leader in cancer diagnostics. Under the terms of the agreement, Cannabics Pharmaceuticals Inc. (OTCMKTS:CNBX) is to become the exclusive global provider of the SIMFO’s CTC diagnostics. Mr. Ballan expects the collaboration to pave way for the development of effective natural anticancer therapy.

The diagnostics in question include a count of circulating tumor cells as well as drug sensitivity tests of different cannabinoids. SIMFO is currently utilizing Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX) cannabinoid formulations as part of preclinical studies on cannabinoid antitumor activity and drug development.

Positive CTC Test Results

Last month, Cannabics received positive results from screening necrosis from cancer patients treated with its cannabinoids CBD and CBDA. The topline results affirm the company’s previously calculated data with regards to anti-tumor activity. The study results also indicate that Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX) proprietary technology can be relied upon in providing supportive data for personalized treatments.

“The screening of CTCs treated with specific cannabinoids and CTC cell count of patients treated with cannabinoids produces an invaluable body of data in our search for effective anti-tumor treatment,” said Mr. Ballan.

Cannabics Pharmaceuticals Inc. (OTCMKTS:CNBX) recently raised $3 million that it plans to use to accelerate the development of a platform for personalized treatments with cannabis. The company plans to expand collaborations with biotech companies in a bid to harness new technologies for examining anti-tumor properties in its R&D lab.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CNBX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Arctic Cat Inc. (Nasdaq: ACAT) Acquired by Textron (NYSE: TXT)

Arctic Cat, Inc. – Nasdaq: ACAT

Arctic Cat, Inc., traded on the Nasdaq under ticker ACAT, has agreed to be purchased by Textron (NYSE: TXT) in an all-cash $247 million deal. The terms of the transaction represent a 40%+ premium to ACAT’s closing price on January 20, 2017.

Christopher Metz, Arctic Cat’s president and chief executive officer stated in a press release “Arctic Cat’s board believes that Textron’s offer delivers compelling and immediate value to our shareholders. This transaction presents increased opportunities for the business to leverage our combined scale, accelerate growth and enhance product innovation in ways that will benefit our customers, dealers and employees.”

Providence, RI-based Textron is a multi-industry company that generates over $13 Billion in annual revenues. ACAT traded at $18.48 in the Nasdaq pre-market at 7:08 AM EST. The per share buyout price for ACAT is $18.50. 

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.